Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
28.6 USD | -0.35% | +1.31% | -6.54% |
Mar. 25 | Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran | CI |
Mar. 08 | Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise | MT |
- Stock
- Equities
- Stock Arrowhead Pharmaceuticals, Inc. - Nasdaq
- News Arrowhead Pharmaceuticals, Inc.